Wutah dodolan YoY sajrone 12 wulan kepungkur: Ironwood Pharmaceuticals, Inc. (IRWD)

Logo grafis ironwoodpharma.com (IRWD)

Is it worth investing in Ironwood Pharmaceuticals (IRWD), a company implementing "green chemistry" principles to reduce production toxicity? The TTM annual sales growth rate provides the answer, where the 18.40 mark characterizes this parameter. The positive trend is based on the expanding market share of Linzess and new drugs for rare gastrointestinal pathologies. High margins are sustained by a powerful brand and an extensive distribution network.

IRWD Wutah dodolan YoY sajrone rolas wulan kepungkur Ironwood Pharmaceuticals, Inc. (11.02.2024 - 19.11.2026)

ironwoodpharma.com (IRWD) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:
Pambiji fundamental perusahaan:Ironwood Pharmaceuticals, Inc.
Produk asil prodhuksi Ironwood Pharmaceuticals

This indicator measures the dynamics of total revenue over the last twelve months relative to the same period last year, allowing for an assessment of the business's actual expansion speed. By analyzing the 12-month year-over-year revenue growth rate, an investor can gauge the commercialization efficiency of Ironwood Pharmaceuticals (IRWD) gastroenterology drugs and the success of its strategy to reduce costs through global partnerships and the development of an innovative pipeline.